Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Provided By GlobeNewswire
Last update: Jan 31, 2025
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD) in the European Union.
Read more at globenewswire.com140.64
+3.56 (+2.6%)
Find more stocks in the Stock Screener
BIIB Latest News and Analysis
11 days ago - ChartmillTop S&P500 movers in Wednesday's sessionStay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
11 days ago - ChartmillThese S&P500 stocks have an unusual volume in today's sessionLet's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
11 days ago - ChartmillThese S&P500 stocks are moving in today's sessionStay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
11 days ago - ChartmillWednesday's session: gap up and gap down stock in the S&P500 indexLet's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session.
